Treat tumour-induced hypercalcaemia where it starts.*

Malignant bone resorption can lead to a number of problems in bone.†

Fortunately tumour-induced hypercalcaemia is a bone complication of bone resorption that responds well to treatment with Aredia.

That's because Aredia prevents bone resorption by osteoclast inhibition.‡

Which is why Aredia has been shown to be so effective in restoring normocalcaemia and bringing relief to patients with tumour-induced hypercalcaemia.§

**AREDIA**

pamidronate disodium

A potent inhibitor of bone

---

*Dosage* 4 mg/day in 250 ml of saline i.v. over 4-6 hours. Duration of therapy depends on the response. Dosage as a single 15 mg i.v. bolus injection is also effective. Not recommended for children.

†Contra-indications Known hypersensitivity to pamidronate disodium or to other bisphosphonates. Precautions Use with caution in renal impairment. Dose must be reduced with other hypocalcaemic treatments and renal impairment. Side-effects Aspiration-type symptoms and taste disorders.

‡Legal category POM - Pack size 100g

Announcing the launch of a new international journal...

GI CANCER
An International Journal of Gastrointestinal Oncology

Editor in Chief
John W. L. Fielding
Department of Surgery, Queen Elizabeth Medical Centre, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK
Tel: +44 (0) 121 627 2272
Fax: +44 (0) 121 627 2273

Associate Editors
William H. Allum UK
David M. Dent South Africa
Bernard Levin USA
David L. Morris Australia
Koichi Maruyama Japan

GI Cancer is the first journal to present the diverse aspects of gastrointestinal cancer under one title. It documents current research and treatment on these cancers which are a major global problem.

The editorial board features internationally recognized scientists and will ensure rapid peer review of manuscripts for prompt publication. Each issue will include an invited review and refereed original research articles, and interesting or unusual case reports will also be published. Articles cover the following research areas:

- biology
- clinical research
- epidemiology
- oncology
- pathology
- radiology
- radiotherapy
- surgery

GI Cancer will be an important reference source for all clinicians and researchers dealing with the diagnosis, clinical care and therapy of patients with gastrointestinal cancer.

4 issues per volume • ISSN 1064-9700 • Current Subscription: Volume 1 (1995) • Price per volume: £66 / $90 / ECU 83

Launch date January 1995  Send now for your free sample copy.

Also of interest...

Neoplastic Diseases of Childhood
Edited by Carl Pochodz, King/Drew Medical Centre, UCLA School of Medicine, Los Angeles, California, USA

This book presents all aspects of pediatric neoplastic diseases, covering a broad range of clinical and biological manifestations and treatment. It focuses on the practical needs of the clinician as well as on the frontiers of clinical and basic research.

1994 • ISBN 3-7186-5340-0 • Hardcover • 1,600 pp (2 volumes) • Price: £290 / $430

☐ Please send me a free sample copy of GI Cancer
☐ Send me further information on Oncology titles from Harwood Academic Publishers

Return this form to: Marketing Department, Harwood Academic Publishers, PO Box 90, Reading, Berkshire, RG1 8JL, UK
Tel: (01734) 560080 Fax: (01734) 568211

Harwood Academic Publishers
Australia, Austria, Belgium, China, France, Germany, India, Japan, Malaysia, Netherlands, Russia, Singapore, Switzerland, Thailand, United Kingdom, United States